Nanoparticles could have giant impact on drug development

05/7/2013 | Reuters

Bind Therapeutics has agreed to three deals potentially worth a total of $1 billion to help drugmakers develop nanomedicine. Drugs incorporating nanoparticles of polymers, gold and graphene are in various stages of development, including 117 oncology drugs, according to Thomson Reuters Pharma. Nanoparticles may allow targeted treatment of tumors with fewer side effects than conventional therapies and may also be useful in drugs for inflammatory disorders, pain, and heart and brain diseases, as well as diagnostics.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide